research use only

Lanreotide GHSR inhibitor

Name: Lanreotide
Brand: Selleck Chemicals
SKU: S6948
Availability: InStock
Rating: 5 (2 reviews)

Cat.No.S6948

Lanreotide (Laromustine, Angiopeptin, BIM 23014, Dermopeptin, ITM-014, Lanreotidum), an analog of the native somatostatin peptide, is a physiological inhibitor of growth hormone (GH). This compound also has antitumoral effects.

Chemical Structure

Molecular Weight: 1096.32

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability

Quality Control

Batch: Purity: 99.75%

99.75

Related Targets	Adrenergic Receptor Estrogen/progestogen Receptor GPR Androgen Receptor Glucocorticoid Receptor ACE RAAS Progesterone Receptor Opioid Receptor THR PGES Aromatase CCK receptor 5-alpha Reductase Mineralocorticoid Receptor SSTR TSH Receptor GNRH Receptor PGDS
Related Products	Anamorelin AnaMorelin hydrochloride

Chemical Information, Storage & Stability

Molecular Weight	1096.32	Formula	C₅₄H₆₉N₁₁O₁₀S₂	Storage (From the date of receipt)	3 years -20°C powder
CAS No.	108736-35-2	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	Laromustine, Angiopeptin, BIM 23014, BIM 23014C, BM 23014, Dermopeptin, ITM-014, ITM-014T, Lanreotidum			Smiles	CC(C)C1NC(=O)C(CCCCN)NC(=O)C(CC2=C[NH]C3=C2C=CC=C3)NC(=O)C(CC4=CC=C(O)C=C4)NC(=O)C(CSSCC(NC1=O)C(=O)NC(C(C)O)C(N)=O)NC(=O)C(N)CC5=CC6=CC=CC=C6C=C5

Solubility

In vitro
Batch:

DMSO : 100 mg/mL (91.21 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : 100 mg/mL

Ethanol : 100 mg/mL

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC₅₀/Ki	growth hormone ^[1]
References	[1] https://pubmed.ncbi.nlm.nih.gov/26743120/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06253897	Not yet recruiting	Gastro-enteropancreatic Neuroendocrine Tumor\|Acromegaly	Ipsen	March 26 2024	--
NCT04649580	Completed	Neuroendocrine Tumours (NET)	Ipsen	April 27 2021	--
NCT04003519	Withdrawn	Acromegaly	Ipsen	April 2020	--
NCT03947762	Terminated	Pancreatic Neuroendocrine Tumor	Ipsen	July 3 2019	--
NCT03012594	Completed	Gastrointestinal Motility Disorder\|Intestinal Disease	Northwell Health\|Ipsen	May 11 2017	Phase 2
NCT03112694	Completed	Neuroendocrine Tumors	Ipsen	April 4 2017	--

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):